It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Bacterial infections are frequent triggers for diabetic ketoacidosis. In this context, delayed antibiotic treatment is associated with increased morbidity and mortality. Unnecessary administration of antimicrobial therapy might however, also negatively impact the prognosis. The usefulness of sepsis markers in diabetic ketoacidosis has not been assessed. Thus, we sought to investigate diagnostic performances of clinical and biological sepsis markers during diabetic ketoacidosis.
Methods
In this monocentric retrospective cohort study, all consecutive episodes of diabetic ketoacidosis (defined as pH ≤ 7.25, glycaemia > 300 mg/dL and presence of ketones) admitted in intensive care unit were included. A proven bacterial infection was defined as bacteriological documentation on any bacterial sample. Clinical (presence of fever: temperature > 38 °C and presence of hypothermia: temperature < 36 °C) and biological markers (whole blood count, neutrophils count, neutrophils-to-lymphocytes count ratio and procalcitonin), recorded at admission, were compared according to the presence or absence of a proven bacterial infection.
Results
Between 2011 and 2018, among 134 episodes of diabetic ketoacidosis, 102 were included (91 patients). Twenty out of 102 were infected. At admission, procalcitonin (median: 3.58 ng/mL vs 0.52 ng/mL, p < 0.001) and presence of fever (25% vs 4%, p = 0.007) were different between episodes with and without proven bacterial infection in both univariate and multivariate analysis. Whole blood count, neutrophils count, neutrophils-to-lymphocytes count ratio and presence of hypothermia were not different between both groups. The diagnostic performance analysis for procalcitonin revealed an area under the curve of 0.87 with an optimal cutoff of 1.44 ng/mL leading to a sensitivity of 0.90 and a specificity of 0.76. Combining procalcitonin and presence of fever allowed to distinguish proven bacterial infection episodes from those without proven bacterial infection. Indeed, all patients with procalcitonin level of more than 1.44 ng/mL and fever had proven bacterial infection episodes. The presence of one of these 2 markers was associated with 46% of proven bacterial infection episodes. No afebrile patient with procalcitonin level less than 1.44 ng/mL had a proven bacterial infection.
Conclusion
At admission, combining procalcitonin and presence of fever may be of value to distinguish ketoacidosis patients with and without proven bacterial infection, admitted in intensive care unit.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France
2 AP-HP, Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, Department of Endocrinology, Diabetology, Metabolic Disease, Avicenne University Hospital, Bobigny, France
3 Rouen University Hospital, Department of Anesthesiology and Critical Care, Rouen, France (GRID:grid.41724.34)
4 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France (GRID:grid.41724.34)
5 Delafontaine Hospital, Department of Endocrinology, Saint-Denis, France (GRID:grid.41724.34)
6 Gustave Roussy, Médecine Intensive Réanimation, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
7 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France (GRID:grid.14925.3b); Sorbonne University, INSERM, Remodeling and Repair of Renal Tissue, UMR S1155, Tenon Hospital, Paris, France (GRID:grid.14925.3b)
8 AP-HP, Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, Department of Endocrinology, Diabetology, Metabolic Disease, Avicenne University Hospital, Bobigny, France (GRID:grid.14925.3b)
9 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France (GRID:grid.14925.3b)